Market Place
Sourcing Support
NEJM: Ph 3 ASCENT-04/KEYNOTE-D19 Trodelvy+Keytruda Supports SoC
21 Jan 2026 //
BUSINESSWIRE
JPM26: Gilead Captures Mood With Yezugo, HIV Data
14 Jan 2026 //
BIOSPACE
JPM26: Gilead Eyes New Deals From A `Position Of Strength`
14 Jan 2026 //
FIERCE BIOTECH
Xilio Therapeutics Highlights Upcoming Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Study Finds HIV Can Evolve To Resist Lenacapavir—At A Cost
07 Jan 2026 //
FIERCE BIOTECH
RAAP: Alternative Funding Programs Put Rare Patients In Jeopardy
07 Jan 2026 //
PR NEWSWIRE
Abbvie, Gilead Gift Themselves Clinical-Stage Cancer Drugs
02 Jan 2026 //
FIERCE BIOTECH
Gilead Licenses Assembly Bio`s Herpes Drugs After Positive Phase
24 Dec 2025 //
INDPHARMAPOST
Gilead Sciences Acquires RP-3467, Pol-ATPase Inhibitor RP 3467
24 Dec 2025 //
BUSINESSWIRE
Gilead pays $35M to license pair of HSV assets from Assembly Bio
24 Dec 2025 //
BUSINESSWIRE
Gilead Sciences To Present At Upcoming Investor Conference
22 Dec 2025 //
BUSINESSWIRE
Gilead, U.S. Government Collaborate To Reduce Medicine Costs
19 Dec 2025 //
BUSINESSWIRE
Gilead Sciences Names Keeley Wettan as EVP, General Counsel
18 Dec 2025 //
BUSINESSWIRE
Gilead`s HIV Single-Tablet Regimen Meets Phase 3 Trial Goal
15 Dec 2025 //
BUSINESSWIRE
Arcus Updates Phase 3 STAR-221 Study, Focuses R&D On Casdatifan
12 Dec 2025 //
PHARMIWEB
Therapy Eases Side Effects for 75% of Black Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
Gilead Foundation Grants $3M For Metastatic Breast Cancer Support
09 Dec 2025 //
BUSINESSWIRE
Gilead, J&J Lead CAR-T In Multiple Myeloma; Fulcrum Soars
08 Dec 2025 //
BIOSPACE
Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
Kite Next-Gen Bicistronic CAR-T Shows Ph1 Promise in Lymphoma
06 Dec 2025 //
BUSINESSWIRE
Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma
06 Dec 2025 //
BUSINESSWIRE
Generic HIV Drug Rollout To Take A Hit On Trial Push
28 Nov 2025 //
ECONOMICTIMES
Gilead Launches Innovative HIV Prevention Drug In Eswatini
25 Nov 2025 //
INDPHARMAPOST
Gilead Hatches $400M Biobucks Deal For Sprint`s TREX1 Program
24 Nov 2025 //
FIERCE BIOTECH
Gilead Foundation Invests $3M To Combat Food Insecurity
24 Nov 2025 //
BUSINESSWIRE
Gilead Abruptly Parts Ways With General Counsel—Chutes & Ladders
21 Nov 2025 //
FIERCE BIOTECH
Merck`s Two-Drug HIV Regimen Hits Phase 3 Success
20 Nov 2025 //
PRESS RELEASE
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
19 Nov 2025 //
BUSINESSWIRE
Galapagos Urged By Gilead To Avoid Extinction
19 Nov 2025 //
FIERCE BIOTECH
Gilead Partners For First Shipments Of Twice-Yearly Lenacapavir
18 Nov 2025 //
BUSINESSWIRE
Gilead`s Bictegravir, Lenacapavir Tablet Meets Mark In Phase 3
13 Nov 2025 //
BUSINESSWIRE
J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
12 Nov 2025 //
FIERCE PHARMA
AHF`s Mobile Billboard Calls Out Gilead`s Greed At Pharma Summit
10 Nov 2025 //
BUSINESS WIRE
Gilead Provides Update On Phase 3 ASCENT-07 Study
07 Nov 2025 //
BUSINESSWIRE
Gilead Livdelzi Shows Sustained Efficacy And ALP Reduction In PBC
07 Nov 2025 //
BUSINESSWIRE
Gilead Sciences To Present At Upcoming Investor Conferences
04 Nov 2025 //
BUSINESS WIRE
Gilead And Kite Show Progress In Blood Cancer Cell Therapy Data
03 Nov 2025 //
BUSINESSWIRE
Gilead Sciences Receives 2025 Prix Galien USA Award For Yeztugo
31 Oct 2025 //
BUSINESSWIRE
HOOKIPA Pharma Completes Sale Of HBV & HIV Assets To Gilead
31 Oct 2025 //
GLOBENEWSWIRE
Gilead Lifts Guidance on Prep Launch Despite Cell Therapy Woes
31 Oct 2025 //
FIERCE PHARMA
Gilead Sciences Announces Third Quarter 2025 Financial Results
30 Oct 2025 //
BUSINESSWIRE
AHF, And 100 Organizations Stop Gilead`s Drug Price Hikes
29 Oct 2025 //
BUSINESSWIRE
Gilead to Present Livdelzi and Bulevirtide Efficacy Data
23 Oct 2025 //
BUSINESSWIRE
80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
21 Oct 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Cuts Breast Cancer Risk by 38% in Trial
20 Oct 2025 //
REUTERS
Kite Puts $1.64B On Line For Pregene`s In Vivo CAR-T Deal
20 Oct 2025 //
FIERCE BIOTECH
Gilead To Present Latest Virology Data At IDWEEK 2025
19 Oct 2025 //
BUSINESSWIRE
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
GSK Tout Study Showing Tolerability Edge for Its Long-Acting PrEP
15 Oct 2025 //
FIERCE PHARMA
Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
14 Oct 2025 //
INDPHARMAPOST
Gilead, Kite Showcase Cancer Care Transformation At ESMO 2025
13 Oct 2025 //
BUSINESSWIRE
Gilead, Arcus Keep TIGIT Dream Alive With 27-Month OS Data
13 Oct 2025 //
FIERCE BIOTECH
Gilead Sciences To Report Q3 2025 Financial Results On October 30
09 Oct 2025 //
BUSINESSWIRE
Gilead Inks Biktarvy Settlements With 3 Generic Drug Makers
07 Oct 2025 //
FIERCE PHARMA
Hanmi`s Oral Delivery Platform Compound Licensed To Gilead
29 Sep 2025 //
PR NEWSWIRE
Gilead Pumps Up Virology Pipeline With Drug Transporter Deal
29 Sep 2025 //
PR NEWSWIRE
TWN Urges Universal $40/year Access To Generic Lenacapavir
26 Sep 2025 //
PHARMABIZ
Gilead Invests $6.5M In STEM Education In San Francisco Bay
25 Sep 2025 //
CONTRACTPHARM
Lupin Gets Tentative FDA Nod For Biktarvy Tablets
25 Sep 2025 //
EXPRESSPHARMA
CDC Strongly Recommends Gilead`s HIV PrEP Yeztugo
19 Sep 2025 //
FIERCE PHARMA
